Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia.

Morales ML, Arenas A, Ortiz-Ruiz A, Leivas A, Rapado I, Rodríguez-García A, Castro N, Zagorac I, Quintela-Fandino M, Gómez-López G, Gallardo M, Ayala R, Linares M, Martínez-López J.

Sci Rep. 2019 Dec 9;9(1):18630. doi: 10.1038/s41598-019-54901-9.

2.

Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy.

Rodríguez-García A, Morales ML, Garrido-García V, García-Baquero I, Leivas A, Carreño-Tarragona G, Sánchez R, Arenas A, Cedena T, Ayala RM, Bautista JM, Martínez-López J, Linares M.

Antioxidants (Basel). 2019 Oct 24;8(11). pii: E508. doi: 10.3390/antiox8110508.

3.

GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.

Fernández L, Fernández A, Mirones I, Escudero A, Cardoso L, Vela M, Lanzarot D, de Paz R, Leivas A, Gallardo M, Marcos A, Romero AB, Martínez-López J, Pérez-Martínez A.

Front Immunol. 2019 Oct 10;10:2361. doi: 10.3389/fimmu.2019.02361. eCollection 2019.

4.

How do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment?

Fernández L, Leivas A, Valentín J, Escudero A, Corral D, de Paz R, Vela M, Bueno D, Rodríguez R, Torres JM, Díaz-Almirón M, López-Collazo E, Martinez-Lopez J, Pérez-Martínez A.

Transfusion. 2018 Jun;58(6):1340-1347. doi: 10.1111/trf.14573. Epub 2018 Mar 14.

PMID:
29542132
5.

Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.

Fernández L, Metais JY, Escudero A, Vela M, Valentín J, Vallcorba I, Leivas A, Torres J, Valeri A, Patiño-García A, Martínez J, Leung W, Pérez-Martínez A.

Clin Cancer Res. 2017 Oct 1;23(19):5824-5835. doi: 10.1158/1078-0432.CCR-17-0075. Epub 2017 Jun 28.

6.

Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma.

Leivas A, Perez-Martinez A, Blanchard MJ, Martín-Clavero E, Fernández L, Lahuerta JJ, Martinez-Lopez J.

Oncoimmunology. 2016 Nov 22;5(12):e1250051. doi: 10.1080/2162402X.2016.1250051. eCollection 2016.

7.

Visfatin/Nampt induces telomere damage and senescence in human endothelial cells.

Villalobos LA, Uryga A, Romacho T, Leivas A, Sánchez-Ferrer CF, Erusalimsky JD, Peiró C.

Int J Cardiol. 2014 Aug 20;175(3):573-5. doi: 10.1016/j.ijcard.2014.05.028. Epub 2014 May 17. No abstract available.

8.

Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity.

Vallejo S, Romacho T, Angulo J, Villalobos LA, Cercas E, Leivas A, Bermejo E, Carraro R, Sánchez-Ferrer CF, Peiró C.

PLoS One. 2011;6(11):e27299. doi: 10.1371/journal.pone.0027299. Epub 2011 Nov 3.

Supplemental Content

Loading ...
Support Center